Company profile
Serina Therapeutics, Inc.
AMEX: SER · Healthcare · Biotechnology
#1030 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
41DFH 26DQ 46GM 66SS 59
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), listing tenure · ↓ operating margin, net margin
Methodology →Revenue TTM
$130.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$19.2M
Employees
16
as of 2026-08-21
Market cap
$39.7M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$130.0k$130.0k2025
Net income-$19.2M-$19.2M2025
Operating income-$24.0M-$24.0M2025
Total assets$7.0M$7.0M2025
Liabilities$7.0M$7.0M2025
Equity-$37.0k-$37.0k2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Grant Revenues100%
By geography
Not disclosed.
The read
What is Serina Therapeutics, Inc.’s revenue?
Serina Therapeutics, Inc. booked $130.0k in FY2025 revenue, growing 132% year over year — faster than most Healthcare companies we track, at a -14755.4% net margin.
Peers · Healthcare
VivoSim Labs, Inc.——Sigyn Therapeutics, Inc.——Endonovo Therapeutics, Inc.——VentriPoint Diagnostics Ltd.31DPanamera Holdings Corporation31DCandel Therapeutics, Inc.33DNeighbors
Madison →Key facts
CEOSteven A. Ledger
SectorHealthcare
IndustryBiotechnology
HeadquartersHuntsville, AL
ExchangeAMEX: SER
Employees16
IPO date2000-01-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.